MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

September 8, 2020

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2026

Conditions
Multiple Myeloma
Interventions
BIOLOGICAL

Infusion of MCARH109 T cells

Patients will be admitted to Memorial Hospital as inpatient prior to the infusion of CAR T cells. The T cell infusion will be planned to start at 2 days following the completion of the conditioning chemotherapy (up to 7 days is allowed if clinically indicated to delay).Cohorts of 3-6 patients each will be treated with escalating doses of modified T cells.

Trial Locations (7)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester (Limited protocol activities), Harrison

11553

Memorial Sloan Kettering Nassau (Limited protocol activities), Uniondale

11725

Memorial Sloan Kettering Suffolk - Commack (Limited protocol activities), Commack

07920

Memorial Sloan Kettering Basking Ridge (Limited protocol activities), Basking Ridge

07748

Memorial Sloan Kettering Monmouth (Limited protocol activities), Middletown

07645

Memorial Sloan Kettering Bergen (Limited protocol activities), Montvale

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER